Several AD therapies under investigation target Aβ or its aggregates and can generally be divided into four therapeutic aims: 1) to reduce Aβ generation; 2) to enhance degradation and clearance of Aβ and its aggregates; 3) to neutralize soluble Aβ monomers or the resulting toxicity; 4) to directly inhibit Aβ aggregation.1 As of August 2023, aducanumab and lecanemab are the only two FDA approved antibody-based drugs, while investigation of 38 therapies have been discontinued due to ineffectiveness or toxic side effects.1-3

Acess our Slide Deck on treatment principles of AD and learn more about pharmacological treatment of AD.

file_download Download in HQ

Related content

image Image A multi-arm, multi-stage platform trial illustration
A multi-arm, multi-stage platform trial illustration
29.04.2025 Alzheimer’s Disease
image Image Drug Delivery Systems to the Brain
Drug Delivery Systems to the Brain

Brain drug delivery systems, allied with their characteristics for overcoming the blood-brain barrier (BBB).

29.04.2025 Alzheimer’s Disease
image Image From One-Size-Fits-All to Precision Medicine
From One-Size-Fits-All to Precision Medicine

The use of a single treatment in heterogeneous populations has proved problematic in clinical trials undertaken in patients with neurodegenerative diseases.

29.04.2025 Alzheimer’s Disease